Poolbeg Pharma PLC names drugmaker ahead of flu trial next month

Preparations continue apace for Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) ahead of its clinical trial of POLB 001, a treatment for severe influenza.

In an update, he said he signed a contract to produce the drug to good manufacturing standards (GMP), so he has enough supplies ready for the next challenge study.

In March, Poolbeg signed a clinical trial agreement with the Center for Human Drug Research, which will evaluate the effectiveness of POLB 001.

The active is being developed to reduce the body’s hyperinflammatory response to influenza.

As such, “POLB 001 has the potential to treat multiple disease indications beyond severe influenza,” Chief Executive Jeremy Skillington pointed out.

Poolbeg’s objective is to find a partner for its drug candidate at the start of its clinical development.

Add related topics to MyProactive

Create your account: subscribe and get ahead of news and events


The Company is a publisher. You understand and agree that nothing posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is…

In return for the publishing services rendered by the Company on behalf of Poolbeg Pharma PLC named herein, including the Company’s promotion of Poolbeg Pharma PLC in any Site Content, the Company receives…